HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

One Year Later, Groups Press Sebelius To Backtrack On OTC Plan B Block

This article was originally published in The Tan Sheet

Executive Summary

The Reproductive Health Technologies Project, plus 45 other organizations and 18 professionals, urge HHS Secretary Kathleen Sebelius to revisit her decision to overrule full OTC availability of Teva’s Plan B One-Step emergency contraceptive.

You may also be interested in...



Physician Group Support Boosts OTC Contraception Chances

The American College of Obstetricians and Gynecologists and the American Academy of Pediatrics recommend OTC availability of hormonal contraception, but pharmaceutical industry Rx-to-OTC switch sponsors remain elusive.

“Status Quo” Election Means Stability in Administration Overseeing Rapid Change in Policy Climate

The re-election of Barack Obama injects some stability into a period of rapid change in regulatory and health policy. Most key health officials are expected to stay at least until 2014, and that is likely to include FDA Commissioner Margaret Hamburg. But there are plenty of big changes in key slots on Capitol Hill, and the implementation of health reform and PDUFA V will mean a lot is new even if the political lineups aren’t.

Teva Plan B OTC Application Fails Political Test After Clearing FDA Hurdle

HHS Secretary Sebelius says Teva must show more evidence of how young adolescent females would use Plan B One-Step as an OTC. But obtaining such clinical data for the emergency contraceptive – in excess of what FDA already needed to approve it – appears nearly impossible, experts say.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS124780

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel